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Kidney and anemia in familial amyloidosis type I.
Background. Familial amyloid polyneuropathy (FAP) type I
is caused by a mutated transthyretin (TTR V30M) and charac-
terized by a sensorimotor and autonomic neuropathy. Renal,
cardiac, and ocular abnormalities can also occur. Anemia has
been described in previous reports, but its prevalence in Por-
tuguese FAP patients is not precisely known. The aim of this
study was to estimate the prevalence of anemia in FAP type
I Portuguese patients and to evaluate the contribution of ery-
thropoietin (Epo) to its genesis.
Methods. A retrospective cross-sectional study was under-
taken to determinate the prevalence and characteristics of ane-
mia in 165 FAP patients. For comparison analysis, 3 control
groups were also evaluated, 1 group of 46 apparently healthy
subjects, 1 group of 17 asymptomatic carriers of FAP-trait, and
a group of 14 non-FAP patients with chronic renal insufficiency.
Serum Epo levels were analyzed in all groups.
Results. Anemia was present in 24.8% of symptomatic FAP
patients. Iron stores, B12 vitamin, and serum folate levels were
normal. FAP patients presented significantly lower serum Epo
levels than healthy controls (P = 0.003). Epo levels were found
lower than expected for the degree of anemia and in 17.5% were
undetectable. Low Epo values were observed independently of
the presence of renal failure or anemia, and sometimes pre-
ceded clinical disease.
Conclusion. Anemia in FAP type I is a common manifesta-
tion. The results clearly suggest a defective endogenous Epo
production in the genesis of the anemia.
Familial amyloid polyneuropathy (FAP) type I
(Portuguese-type) is the most common form of heredi-
tary amyloidosis, caused by an amyloidogenic variant of
thransthyretin with a substitution of methionine for va-
line at position 30 (TTR V30M). This hereditary disease,
of autosomal-dominant transmission, has a high preva-
lence in Portugal. In fact, Portugal represents the largest
focus of disease worldwide, and the carrier frequency in
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the region of Povoa de Varzim/Vila do Conde was esti-
mated at 186 × 10−5, 1 in every 538 individuals [abstract;
Sousa A, J Rheumatology 20:190, 1993]. The main ex-
pression of this disease is a sensorimotor and autonomic
neuropathy, but other manifestations, such as nephropa-
thy (proteinuria and renal failure), ocular, and hemato-
logic abnormalities can occur. The disease is progressive,
highly disabling, and death occurs on average 11 years
after the onset.
Anemia in FAP V30M is not well characterized. Mod-
erate normocytic normochromic anemia was observed in
39% of the Swedish FAP patients and classified as anemia
of chronic disease with iron metabolism abnormalities [1].
Macrocytic and hypochromic anemia was reported in a
group of 35 Japanese FAP patients [2]. In a previous study
of 38 Portuguese anemic FAP patients, we have shown
that serum levels of erythropoietin (Epo) were low for
the degree of anemia [3]. Normalization of iron status
was insufficient for the correction of anemia, which re-
sponded, however, to the administration of recombinant
human erythropoietin [3].
In order to evaluate the dimension of this problem
in a large Portuguese FAP population, a retrospective
cross-sectional study was undertaken to determine the
prevalence and characteristics of anemia in a representa-
tive sample of the FAP population, and to define the de-
mographic, clinical, and laboratory data associated with
anemia.
METHODS
FAP patients
Clinical data from 165 patients, randomly selected from
a total of 400 FAP patients followed at our outpatient
clinic, were collected for the present analysis. All pa-
tients had the TTR V30M mutation confirmed by the
detection of TTR Met30 in serum, using immunoblotting
procedure, and by DNA analysis. FAP patients submitted
to liver transplant, with concomitant pathology, or being
treated with myelotoxic drugs, were excluded. The sam-
ple population consisted of 90 males aged 21 to 71 years,
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and 75 females aged 28 to 73 years. The disease had, on
average, an evolution time of 6 years (0.5–18 years). The
age at onset of symptomatic disease was, on average, 35 ±
11 years, as expected in the Portuguese FAP population
[4].
Control groups
A group of 46 apparently healthy adults (15 males, 31
females, aged 26 to 68 years), randomly recruited among
the population of blood donors of Santo Anto´nio General
Hospital Blood Bank and laboratory staff, were used as
reference for the laboratory parameters analyzed. Four of
them were found with asymptomatic anemia (Hbg values,
9.2–11.5 g/dL) associated with iron deficiency.
A group of 17 asymptomatic carriers of the gene muta-
tion TTR V30M (5 males, 12 females, aged 21 to 69 years)
was characterized for all parameters studied. One of
them was excluded due to the presence of microcytic
anemia associated with iron, vitamin B12, and folic acid
deficiencies.
In addition, Epo levels were evaluated in a group of 14
patients with mild to moderate chronic renal insufficiency
randomly selected from the nephrology outpatient clinic.
Patients with diabetes or renal cysts were excluded. The
clearance of creatinine was, on average, 33.9 ± 15.1 (9.4–
62.7) mL/min.
All controls were enrolled after informed consent, and
approval of the local ethical committee was obtained.
Clinical and laboratory parameters
The demographic and clinical data analyzed were: age,
sex, the evolution time of neuropathy, and presence and
duration of infection. All patients were evaluated by the
same medical team, and categorized according to a mod-
ified disability scoring system for neurologic symptoms:
score I, sensory disturbances in the extremities, but pre-
served walking capacity; score II, difficulties in walking,
but without the need for a walking stick; score IIIA, one
walking stick or one crutch required for walking; score
IIIB, two walking sticks or crutches required; and score
IV, patients in a wheelchair, or bed confined. Present-
ing symptoms were sensitive neuropathy in 75.5% of pa-
tients, weight loss in 40%, diarrhea and/or constipation
in 25.7%, and vomiting in 10%. Sexual dysfunction was
a presentation symptom in 45.8% of men. At the evalu-
ation time, the neurologic involvement was classified as
stage 0 to II in 69% of patients, stage III in 19.5%, and
stage IV in 11.5%.
Laboratory data collected for each group included
the hematologic parameters hemoglobin (Hgb), hemat-
ocrit (Hct), mean corpuscular volume (MCV), mean cor-
puscular hemoglobin concentration (MCHC), leukocyte
counts; the serum levels of iron, transferrin, ferritin, trans-
ferrin saturation, vitamin B12, folates, creatinine, urea,
and erythropoietin; and proteinuria. Reference values
for serum Epo levels were first established in the healthy
control population without anemia (N = 40). The aver-
age serum Epo level was 10.3 ± 2.3 (4.1–23) mU/mL, in
accordance with published data [5]. A significant correla-
tion was found between Epo and hemoglobin values (r =
0.458; P = 0.003). In order to define erythropoietin levels
as appropriate or inappropriate for a given hemoglobin
level, the observed values were systematically compared
with the expected values, estimated according to the log-
arithmic regression equation of Epo against hemoglobin
in control subjects. The regression equation was: Epo =
75.19–24.77 × Ln (Hbg). In addition, to define the ex-
pected Epo values in the presence of anemia, a new log-
arithmic regression equation of Epo against hemoglobin
was obtained in the control population including anemic
subjects (N = 46). The regression equation was: Epo =
208.66–75.377 × Ln (Hbg) (r = 0.742; P = 0.0001).
Definitions
For the purpose of statistical analysis, FAP patients
were divided in 4 groups: 1, FAP with anemia and nor-
mal renal function; 2, FAP with anemia and chronic renal
insufficiency; 3, FAP without anemia and normal renal
function; 4, FAP without anemia and chronic renal insuf-
ficiency (CRI).
Anemia
Anemia was considered for hemoglobin levels lower
than 11.5 mg/dL in men, and lower than 11.0 mg/dL in
women. These cut-off values are routinely used in our
current protocols as markers to decide to treat anemia,
in accordance with European guidelines to the treatment
of anemia of chronic renal failure [6].
Chronic renal insufficiency and estimation
of kidney function
Patients with glomerular filtration rate (GFR) of 60 to
41 mL/min, 40 to 21 mL/min, and 20 mL/min or below are
classified as having mild, moderate, and advanced degrees
of chronic renal insufficiency, respectively [7]. Due to
the inability of many patients to accurately collect timed
urine samples, the creatinine clearance was estimated by
the Cockcroft-Gault equation, corrected for women and
low muscular mass. Kidney function estimated by cre-
atinine/creatinine clearance in patients with nephrotic
syndrome could be overestimated compared with the
function obtained by Cr-EDTA clearance. In a subgroup
of 15 patients (11 males, 4 females) with a mean serum cre-
atinine of 0.94 ± 0.21 (0.6–1.3), the estimation of the re-
nal function was done in parallel by the Cockcroft-Gault
equation and by the radionuclide markers: 99mTc-DTPA
(N = 12) and 99mTc-MAG3. We verified that GFR evalu-
ated by radionuclide markers was, on average, 5 mL/min
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lower than that estimated by the Cockcroft-Gault equa-
tion (data not shown). Based on these results, we defined
renal insufficiency when creatinine clearance by radionu-
clide markers was lower than 60 mL/min, corresponding
to a creatinine clearance by Cockcroft-Gault equation
lower than 65 mL/min.
Autonomic dysfunction
Autonomic dysfunction was considered when one or
more of the following symptoms were present: ortho-
static hypotension, gastrointestinal motility disturbances,
bladder dysfunction, or rhythm disturbances motivating
a definitive pacemaker implantation.
Statistical analysis
Results were expressed as mean ± standard deviation
or median (interquartile range), unless otherwise stated.
Continuous variables distribution was assessed by
Kolmogorov-Smirnov test.
Linear regression analysis was used to estimate the
coefficients of the linear equation that best predict the
value of the dependent variable (erythropoietin) from
hemoglobin as an independent variable.
Differences between values of related data (observed
and expected Epo) were analyzed by Student t test for
paired samples or Wilcoxon signed-rank test. Continu-
ous variables were compared between groups by Student
t test for independent samples. The correlation analy-
sis between quantitative variables was performed using
Pearson’s correlation test.
All data were analysed with SPSS software for Win-
dows (version 11.5, Chicago, IL, USA), and a P value of
less than 0.05 was considered statistically significant.
RESULTS
Prevalence of anemia in FAP patients
Anemia was present in 41 of 165 symptomatic FAP
patients (24.8%), similar in both genders (Table 1). In all
cases, the anemia was normochromic and normocytic, and
no abnormalities in serum folic acid or serum vitamin B12
were found. Although low transferrin saturation values
(≤10%) were found in 14 anemic patients (2 males and 3
females with NRF; 2 males and 7 females with CRI), only
2 patients had laboratory criteria of concomitant iron de-
ficiency (i.e., abnormally low values of both transferrin
saturation and serum ferritin). In the remaining patients,
serum ferritin values were normal to high. The distribu-
tion of patients according to the defined clinical groups
(see Methods) and the laboratory parameters analyzed
for characterization of anemia are summarized in Table 2.
The clinical characterization of anemic patients in com-
parison with the nonanemic patients is summarized in
Table 1. The anemic patients had, on average, an evolu-
Table 1. Demographic and clinical data of the anemic and
nonanemic patients
Anemia No anemia
Number of patients 41 124
Male/Female 22/19 68/56
Age years 43 ± 9 41 ± 11.8 NS
Disease evolution time 9 ± 5 5 ± 4 P = 0.003
Neurologic stage
Stage I—II 19 (46.4%) 93 (75%)
Stage III 13 (31.7%) 18 (14.5%)
Stage IV 9 (21.9%) 13 (10.5%)
Renal failure 31 (75.6%) 30 (24.2%)
Creat Cl ≥41 mL/min 19/31 (61.3%) 7/30 (23.3%)
Proteinuria >1 g/day 15/41 (36.6%) 15/124 (12.1%)
History of infection 19 (46.4%) 21 (16.9%)
Duration >1 month 6/19 8/21
Leukocytes/mm3 8.03 ± 3.6 7.17 ± 1.9 NS
Lymphocytes/mm3 1.5 ± 0.4 1.97 ± 1.5 NS
Anemic patients had a more severe neurologic involvement, and a higher
prevalence of infection.
tion time of symptomatic disease significantly higher (P =
0.003) than nonanemic patients (9.0 and 5.0 years, re-
spectively), with a more severe neurologic involvement.
Chronic renal insufficiency was present in 75.6% of the
anemic patients (creatinine clearance ranging from 22.6–
64.5 mL/min), and was classified as mild (equal or higher
to 41 mL/min) in 19 of the 31 anemic patients with chronic
renal insufficiency (61.3%). In the group of the nonane-
mic patients, renal insufficiency was present in 24.2% of
them. Concomitant infection was observed at the time of
evaluation in 18 patients. The most common infections
were acute urinary tract infections (in 8 patients) and
infected wounds (in 8 patients, 6 chronically infected).
Pneumonia was present in 1 case, and cholecystitis in an-
other case. The presence of infections was more com-
mon in anemic than in nonanemic patients, although the
prevalence of chronic infection (duration >1 month) was
similar in both groups. No significant differences were ob-
served on leukocyte or lymphocyte counts between the
2 groups. No correlation was found between the presence
of infection and serum Epo levels (data not shown).
Erythropoietin levels in FAP patients
Serum erythropoietin levels were evaluated in a total
of 124 symptomatic FAP patients (75.2%). In order to
classify the individual Epo serum levels as appropriate or
not for the degree of anemia, the ratio of observed to ex-
pected Epo (O/E) values was determined in all patients
and compared among groups. The results are summarized
in Table 3. In general, FAP patients presented with sig-
nificantly lower serum erythropoietin levels than healthy
control patients (P = 0.003). In 21 patients (17.5%), the
O/E Epo ratio was lower than 0.25, with undetectable lev-
els in 9 of them. In all FAP groups, the observed Epo levels
were, on average, lower than expected for the hemoglobin
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Table 2. Comparative analysis of laboratorial data from FAP patients and control groups: healthy, diabetics, chronic renal insufficiency (CRI),
and asymptomatic gene carriers (AC)
Anemia No anemia
FAP patients FAP patients Control groups
NRF CRI NRF CRI AC CRI Healthy
(N = 7) (N = 28) (N = 61) (N = 28) (N = 16) (N = 14) (N = 40)
Hbg g/dL 9.2 ± 1.9a 9.6 ± 1.1 13.9 ± 1.4 12.6 ± 1.0 13.6 ± 1.2 12.2 ± 1.7 13.8 ± 1.3
MCV fl 86.7 ± 13.9 91.9 ± 5.1 91.4 ± 3.8 93.9 ± 3.4 90.5 ± 4.8 91.5 ± 9.0 89.0 ± 5.0
MCHC g/dL 32.7 ± 2.1 32.9 ± 1.3 34.0 ± 0.8 33.4 ± 1.1 34.2 ± 0.6 33.6 ± 1.0 34.0 ± 1.0
Transferrin saturation % 15.3 ± 12.0 19.2 ± 14.3 30.9 ± 13.5 33.2 ± 18.1 31.7 ± 10.4 24.2 ± 7.3 28.0 ± 10.0
Ferritin ng/mL 204.6 ± 172.8 161.1 ± 147.4 96.1 ± 77.1 137.3 ± 160.5 59.1 ± 50.6 158.7 ± 105.5 63.2 ± 152.5
NFR, normal renal function; CRI, chronic renal insufficiency. All parameters were in normal range except serum erythropoietin, present in low levels independently
of the presence or absence of anemia or renal failure.
aResults presented as mean ± standard deviation.
Table 3. Observed (O) and expected (E) erythropoietin levels in all study groups
Anemia No anemia
FAP patients FAP patients Control groups
NRF CRI NRF CRI AC CRI Healthy
(N = 7) (N = 28) (N = 61) (N = 28) (N = 16) (N = 14) (N = 40)
Creatinine clearance (mL/min) 77.6 ± 10.2a 43.0 ± 11.7 104.1 ± 21.1 55.1 ± 17.3 111.8 ± 30.4 33.9 ± 15.1 105.2 ± 19.7
Observed EPO (mU/mL) 46.2 ± 57.4c 13.8 ± 13.0e 7.9 ± 4.4d 9.3 ± 5.9 9.2 ± 3.7 14.7 ± 7.9 10.3 ± 5.0
Expected EPO (mU/mL) 43.3 ± 17.1 38.8 ± 9.3 10.1 ± 2.5 12.1 ± 2.6 11.9 ± 4.7 13.5 ± 3.2 10.3 ± 2.3
Epo O/E <0,8 4 (57%)b 27 (96%) 31 (51%) 19 (68%) 7 (44%) 5 (36%) 13 (28%)
Epo O/E 0.8–1.2 1 (14%) 0 20 (33%) 6 (21%) 8 (50%) 2 (14%) 21 (46%)
Epo O/E >1.2 2 (29%) 1 (4%) 10 (16%) 3 (11%) 1 (6%) 7 (50%) 12 (26%)
The number of patients and respective percentage with a ratio O/E Epo <0.8, 0.8–1.2, and >1.2 are presented.
aResults presented as mean ± standard deviation.
bNumber of patients and percentage.
cThe anemic FAP and normal renal function patients group includes 1 patient with 2 years of clinical disease, an iron deficiency anemia, and serum Epo level of 163
mU/mL. After excluding this patient, the average serum Epo level in this group was 26.7 ± 27.7 mU/mL for an expected level of 39.4 ± 15.1 mU/mL.
dP < 0.005.
eP < 0.0001
level, except in the group of anemic FAP with normal re-
nal function (see Table 3). Differences between observed
and expected Epo levels were most highly significant in
the groups of FAP patients with renal insufficiency ei-
ther presenting with anemia (P < 0.0001) or not (P =
0.0005). Surprisingly, a highly significant difference was
also observed in the group of FAP patients who had nei-
ther CRI nor anemia (P = 0.003), and also in the group of
asymptomatic carriers of the gene mutation TTR V30M
(P = 0,03). In all control groups, including the group with
non-FAP CRI, no differences between observed and ex-
pected Epo levels were seen (see Table 3). In order to
evaluate the influence of proteinuria on Epo serum levels,
FAP patients were divided into 2 subgroups, with protein-
uria >1 g/day (N = 27), and proteinuria <1 g/day (N =
97). The average Epo level was not different between the
subgroups with or without proteinuria >1 g/day (12.9 ±
15.4 mU/mL and 11.4 ± 17.6 mU/mL, respectively).
The relative frequencies of subjects with observed Epo
levels lower (O/E <0.8), similar (O/E = 0.8–1.2), or
higher (O/E >1.2) than expected was evaluated in all
study groups (see Table 3). A clear shift to low O/E values
is observed in FAP patients. The shift is already evident in
asymptomatic carriers of the gene mutation TTR V30M
(O/E <0.8 in 44%), is increasingly higher with clinical
disease without CRI (O/E <0.8 from 51%–57%), and is
maximal in the presence of CRI and anemia (O/E <0.8
in 96%).
Erythropoietin levels in asymptomatic carriers of the
gene mutation TTR V30M
The 16 asymptomatic carriers of the gene mutation
TTR V30M presented with serum haemoglobin levels, on
average, 13.6 ± 1.2 g/dL. As described before, observed
serum erythropoietin levels were lower than the expected
in 44% of subjects (N = 7). The time of follow-up after the
laboratory evaluation was, on average, 20.2 ± 10.7 (7–42)
months. During this period, 6 AC became symptomatic,
on average, after 18.1 ± 10.9 (2–22) months. The other
10 individuals remained free of symptoms after 21.4 ±
11 months of follow-up. These include 6 of the 7 patients
who presented with O/E Epo <0.8.
Erythropoietin levels and autonomic dysfunction
FAP patients were divided in 2 subgroups according to
the presence (N = 32) or absence (N = 29) of clinical au-
tonomic dysfunction. Patients with dysautonomy had an
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average Epo value of 8.2 ± 4.8 mU/mL, not significantly
different from the average value presented by those with-
out dysautonomy (7.8 ± 4.0 mU/mL; P = 0.719). In
spite of a more severe autonomic dysfunction in anemic
FAP patients (orthostatic hypotension, 58%, pacemaker,
19.4%) than in nonanemic patients (orthostatic hypoten-
sion, 22%, pacemaker, 7.5%), no significant differences
on Epo levels were found between patients with or with-
out autonomic disturbances.
Erythropoietin levels and chronic renal
insufficiency (CRI)
In order to evaluate the impact of CRI on Epo levels
outside the setting of FAP, a control group of non-FAP
patients with CRI was analyzed for serum Epo. The av-
erage clearance of creatinine in this group was 33.9 ±
15.1 mL/min, and the mean hemoglobin level was 12.2 ±
1.7 g/dL (see Table 3). No significant differences were
seen between the observed and expected Epo levels. The
observed Epo level was 14.7 ± 7.9 mU/mL for an aver-
age expected Epo level of 13.5 ± 3.2 mU/mL. In spite of
a more severe renal insufficiency in this group compared
with the nonanemic FAP patients analyzed (creatinine
clearances of 33.9 ± 15.1 mL/min and 55.1 ± 17.3 mL/min,
respectively), the average observed Epo level was higher
in the first group.
DISCUSSION
Anemia in FAP is a common feature, occurring in
24.8% of the Portuguese patients analyzed in the present
study. Its appearance was late, on average after 9 years
of symptomatic disease, and affected males and females
equally. The anemia was normocytic and normochromic.
B12 vitamin and folate serum levels were normal, and
iron stores were also normal in most of the patients.
Therefore, a deficiency of those nutrients could not be
implicated in the genesis of the anemia. Inappropriately
low Epo levels were commonly observed in FAP patients,
even at early clinical stages of disease, independent of the
presence of chronic renal insufficiency, pointing to a pu-
tative role of Epo deficiency in the genesis of anemia in
FAP.
Several clinical conditions are known to be associated
with low serum Epo levels. In chronic renal insufficiency, a
decreased Epo production leads to anemia, usually with
creatinine clearance lower than 40 mL/min/1.73 m2 [8].
Therefore, the presence of CRI in FAP patients is a rel-
evant parameter to explain, at least in part, the finding
of inappropriately low Epo values in anemic patients. It
does not explain, however, the consistent finding of in-
appropriately low Epo levels in other groups of patients
without CRI, or in asymptomatic carriers of the gene mu-
tation TTR V30M, preceding clinical disease. Moreover,
Epo levels were lower in FAP patients than in control
non-FAP patients with a greater degree of CRI.
Anemia with low serum Epo levels has also been re-
ported in chronic inflammatory diseases [9–12]. Inflam-
matory cytokines inhibit the production of erythropoietin
as well as the growth of erythroid progenitor cells, impair-
ing the response to recombinant erythropoietin [13–15].
Consequently, in these situations, the response to treat-
ment with recombinant erythropoietin (rhEpo) is usually
“blunted.” A preliminary study performed in 38 of the pa-
tients reported here had shown a great improvement of
anemia when treated with low doses of rhEpo [3], there-
fore not supporting the hypothesis of an inhibitor role of
cytokines in the defective production of Epo and blood
marrow response.
The presence of nephrotic syndrome may contribute
to reduce the Epo production [16–20]. This possibility
was excluded in the present group of FAP patients by
the finding of similar values in patients with or without
proteinuria.
Although autonomic neuropathy is involved in the gen-
esis of anemia [21], in the present study, the Epo lev-
els were not significantly different between FAP patients
with or without clinical autonomic disturbances, suggest-
ing that other factors are involved in the decrease of ery-
thropoietin production.
Taken together, the results presented here suggest that
an important defective production of Epo may occur in
TTR V30M FAP, a defect that may be worsened by the
presence of mild renal insufficiency. The mechanism how
Epo production could be impaired in this condition is still
not known.
Hypoxia is generally considered the major stimulus for
the erythropoietin production, with rapid increase in re-
nal production of Epo through an exponential increase in
the number of Epo-producing cells [22]. The precise na-
ture of the mammalian oxygen sensor remains unclear,
several lines of evidence indicating that is a heme protein
[23]. In the adult, the kidney is the major site of erythro-
poietin production. The Epo-producing cells were iden-
tified as fibroblast-like type I interstitial cells, localized
in the peritubular interstitium [24–26]. The inability to
create a cellular line of Epo-producing cells from kid-
ney suggests that the expression of these cells depends
on interstitial environment. In a previous study we have
shown that interstitial amyloid deposits in renal biopsy
were always present in the medullary zone, even in the
absence of clinical nephropathy. In the presence of pro-
teinuria and/or renal insufficiency, the renal cortex was
also involved with additional glomerular and vascular de-
posits [27]. The low levels of Epo in FAP patients, even in
carriers of the TTR V30M mutation, the inability to re-
spond to anemia with an increase in erythropoietin pro-
duction in absence of renal failure, and the development
of anemia with mild renal insufficiency (mean creatinine
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clearance of 43 mL/min) suggest a decrease of interstitial
producing-Epo cells or unfavorable interstitial conditions
that block the Epo-producing cells expression. These ab-
normalities could be related to the presence of amyloid
deposits in the renal interstitium. The low Epo levels ob-
served in asymptomatic carriers could be explained either
by the presence of early renal amyloid deposits, or the
influence of factors other than amyloid itself in the Epo-
producing cells expression, and consequently, the Epo
production.
CONCLUSION
The use of recombinant human erythropoietin proved
to be efficient in the treatment of these patients [3], which
suggests a normal functional bone marrow. It seems clear
that anemia in FAP type I is caused by a defective endoge-
nous Epo production and should constitute an indication
for recombinant human erythropoietin use outside the
setting of uremia.
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